Author

Z. Sychev

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

J. M. Drake· 2 shared A. Agarwal· 1 shared A. J. Armstrong· 1 shared A. Petersen· 1 shared A. V. Sheahan· 1 shared B. C. Thomas· 1 shared B. J. Puviindran· 1 shared C. Morrissey· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. M. Drake

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

K. E. Ware, S. Gupta, J. Eng, G. Kemeny, B. J. Puviindran, W.-C. Foo, L. A. Crawford, R. G. Almquist, D. Runyambo, B. C. Thomas, M. U. Sheth, A. Agarwal, M. Pierobon, E. F. Petricoin, D. L. Corcoran, , J. Somarelli

This study identifies p38/MAPK pathway activation as a convergent mechanism driving survival, immune evasion, and metastasis in hormone-resistant prostate cancer.

bioRxiv · Apr 22, 2020 · PreprintCancer Biology

Targeting RET Kinase in Neuroendocrine Prostate Cancer

H. VanDeusen, J. R. Ramroop, K. L. Morel, A. V. Sheahan, Z. Sychev, N. A. Lau, L. C. Cheng, V. Tan, Z. Li, A. Petersen, J. K. Lee, J. Wook Park, R. Yang, I. Coleman, O. N. Witte, , J. M. Drake

The paper identifies RET kinase as a targetable driver in neuroendocrine prostate cancer (NEPC) through phosphoproteomics and pharmacological inhibition studies, showing reduced tumor growth in models.

bioRxiv · Apr 29, 2019Cancer Biology